The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -65,712 | -108,494 |
| Share-based compensation expense | 7,495 | 13,427 |
| Depreciation expense | 356 | 565 |
| Accretion of asset retirement obligation | 23 | - |
| Non-cash lease expense | 621 | 972 |
| Accretion of net investment discounts | 3,291 | 9,537 |
| Prepaid expenses and other current assets | 2,177 | 5,109 |
| Other non-current assets | 397 | 1,096 |
| Accounts payable | 8,806 | 966 |
| Accrued expenses and other current liabilities | 3,881 | 2,611 |
| Operating lease liabilities | -601 | -1,092 |
| Net cash used in operating activities | -50,996 | -106,787 |
| Purchases of short-term investments | 248,824 | 204,932 |
| Proceeds from maturities of short-term investments | 195,919 | 288,453 |
| Purchases of property and equipment | 1,572 | 546 |
| Advance payment received for sale of non-financial asset | 5,158 | - |
| Net cash provided by (used in) investing activities | -49,319 | 82,975 |
| Proceeds from issuance of ordinary shares-At Market Common Stock Offering Program | 57,058 | - |
| Payments of offering costs | 770 | - |
| Proceeds from issuance of ordinary shares under employee share purchase plan | 0 | 474 |
| Proceeds from exercise of share options | 377 | 1,008 |
| Payment of taxes on restricted share units withheld for taxes | 462 | 156 |
| Net cash provided by financing activities | 56,203 | 1,326 |
| Net change in cash and cash equivalents | -44,112 | -22,486 |
| Cash and cash equivalents at beginning of period | 169,510 | - |
| Cash and cash equivalents at end of period | 102,912 | - |
Structure Therapeutics Inc. (GPCR)
Structure Therapeutics Inc. (GPCR)